# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- New digital health solution for heart failure management puts patients at the center of their care by providing ability for a...
First regimen approved in advanced urothelial cancer to demonstrate superiority to platinum-containing chemotherapy, the stan...
HIGHLIGHT 1™ study to evaluate fezolinetant for treatment of moderate to severe vasomotor symptoms in women with stage 0-3 horm...
Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments ...
- If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted therapy approved...
- If approved, enfortumab vedotin in combination with pembrolizumab will be the first and only treatment to offer an alternativ...
- Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid ...
TANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-meta...